Protocols for the Use of Cyproterone,Medroxyprogesterone,and Leuprolide in the Treatment of Paraphilia

Santen RJ . The testis. In: Felig P Baxter JD Frohman LA , editors. Endocrinology and metabolism. 3rd ed. New York: McGraw-Hill; 1995. p 885–972.

Santen RJ Bardin CW . Episodic luteinizing hormone secretion in man: Pulse analysis, clinical interpretation, physiologic mechanism. J Clin Invest 1973;52:2617–28.

Jackson GL Kuehl D Rhim TJ . Testosterone inhibits gonadotropin-releasing hormone pulse frequency in the male sheep. Biol Reprod 1991;24:188–94.

Santen RJ Demers LM Max DT Smith J Stein BS Gloden LM . Long term effects of administration of a gonadotropin releasing hormone superagonist analog in men with prostatic carcinoma. J Clin Endocrinol Metab 1984;55:397–403.

Geller J . Overview of enzyme inhibitors and anti-androgen in prostatic cancer. J Androl 1991;12:364–70.

Kappy M Stuart T Perelman A Clemons R . Suppresion of gonadotropin secretion by a long acting gonadotropin releasing hormone analog (leuprolide acetate, lupron depot) in children with precocious puberty. J Clin Endocrinol Metab 1989;69:1087–9.

McEvoy G , editor. AHFS drug information. Bethesda (MD): American Society of Health System Pharmacists; 1999.

Neumann F Kalmus J . Cyproterone acetate in the treatment of sexual disorders: Pharmacological base and clinical experience. Experimental and Clinical Endocrinology 1991;98(2):71–80.

Bezchlibnyk-Butler KZ Jeffries JJ , editors. Clarke Institute handbook of clinical psychopharmacology. 6th ed. Toronto: Hogrefe and Huber; 1996.

Conn PM Crowley WF Jr. , Gonadotropin-releasing hormone and its analogues. N Engl J Med 1990;324:93–103.

Thibaut F Cordier B Kuhn JM . Effect of a long-lasting gonadotrophin hormone-releasing hormone agonist in six cases of severe male paraphilia. Acta Psychiatr Scand 1993;87:445–50.

Rosier A Witztum E . Treatment of men with paraphilia with a long-acting analogue of gonadotropin-releasing hormone. N Engl J Med 1998;338:416–22.

Cooper AJ Sandhu S Losztyn S Cernovsky Z . A double-blind placebo controlled trial of medroxyprogestersone acetate and cyproterone acetate with seven pedophiles. Can J Psychiatry 1992;37:687–93.

Rao MV Roy GK Prasannalata SN . Effect of medroxyprogesterone acetate and testosterone enanthate on vas deferens of rats. Indian J Exp Biol 1998;36:157–61.

Avari KM Bhiwgade DA . Effect of depot medroxyprogesterone acetate and testosterone anathate on the testis of albino rats: Ultrastructural and biochemical studies. Indian J Exp Biol 1992;30:1118–27.

Vallis K Waxman J . Tumour flare in hormone therapy. In: Stroll BA , editor. Endocrine management of cancer. 2: Contemporary therapy. Basel (Switzerland): Karger; 1988. p 144–52.

Morsi A Jamal S Silverberg JDH . Pituitary apoplexy after leuprolide administration for carcinoma of the prostate. Clin Endocrinol 1996;44:121–4.

de Voogt HJ Smith PH Pavone-Macaluso M de Pauw M Suciu S . Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: Results from European Organization for Research on Treatment of Cancer trials 30761 and 30762. J Urol 1986;135:303–7.

Pierce EJ . Angina pectoris and myocardial infarction with the use of leuprolide acetate. Am J Obstet Gynecol 1995;172(4 Pt 1):1323.

Canadian Pharmaceutical Association. Compendium of pharmaceutical and specialties. Ottawa: Canadian Pharmaceutical Association; 1996.

Saruki K Sekihara T Mashimo M Matsuo H Sekiguchi H . Leuprorelin acetate blood levels and dialysance after the administration of sustained-release leuprorelin acetate in a dialysis case complicated by prostate cancer. Prostate 1998;34:191–4.

Strum SB McDermed JE Scholz MC Johnson H Tisman G . Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 1997;79:933–41.

Roila F Crino L Carloni G Natalini G . Cyproterone acetate: Hepatotoxicity and prostate cancer treatment. Ann Oncol 1993;4:701.

Parys BT Hamid S Thomson RG . Severe hepatocellular dysfunction following cyproterone acetate therapy. Br J Urol 1991;67:312–3.

Smith JA . A prospective comparison for symptomatic hot flashes following endocrine therapy for carcinoma of the prostate. J Urol 1994;152:132–4.

Schot LPC Schuurs AHWM . Pathophysiology of bone loss in castrated animals. J Steroid Biochem Mol Biol 1990;37:461–5.

Stepan JJ Lachman M Zverina J Pacovsky V Baylink DJ . Castrated men exhibit bone loss: Effect of calcitonin treatment on biochemical indices of bone remodelling. J Clin Endocrinol Metab 1989;69:523–7.

Li M Jee WS Ke HZ Tang LY Ma YF , Liang XG, and others. Prostaglandin E₂ administration prevents bone loss induced by orchidectomy in rats. J Bone Miner Res 1995;10:66–73.

Schot LP Schuurs AH . Sex steroids and osteoporosis: Effects of deficiencies and substitute treatments. J Steroid Biochem Mol Biol 1990;37:167–88.

Jackson JA Michael K . Osteoporosis in men: Diagnosis, pathophysiology, and prevention. Medicine 1990;69:137–52.

Sotaniemi EA Hynnynen T Ahlqvist J Ahokas JT Puoskari U Pelkonen I . Effects of medroxyprogesterone on the liver function and drug metabolism of patients with biliary cirrhosis and chronic active hepatitis. J Med 1978;9:117–28.

Rautio A Sotaniemi EA Pelkonen O Luoma PV . Treatment of alcoholic cirrhosis with enzyme inducers. Clin Pharmacol Ther 1980;28:629–37.

Abramson FP Moore CF Sr Hill MD . Medroxyprogesterone acetate does not induce antipyrine clearance and only weakly increases alpha 1-acid glycoprotein in beagle dogs. Research Communications in Chemical Pathology and Pharmacology 1986;53:65–78.

Gotz VP Dolly FR Block AJ . Influence of medroxyprogesterone on theophylline disposition. J Clin Pharmacol 1983;23:281–4.